Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance)

Cancer

Volumn 120, Issue 22, 2014, Pages 3575-3583

  Barton, Debra L ^a   Thanarajasingam, Gita ^a   Sloan, Jeff A ^b   Diekmann, Brent ^b   Fuloria, Jyotsna ^c   Kottschade, Lisa A ^a   Lyss, Alan P ^d   Jaslowski, Anthony J ^e   Mazurczak, Miroslaw A ^f   Blair, Scott C ^g   Terstriep, Shelby ^h   Loprinzi, Charles L ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO CLINIC   (United States)

^c Ochsner CCOP   (United States)

^d Heartland Cancer Research CCOP   (United States)

^e St Vincent Regional Cancer Center CCOP   (United States)

^f Sioux Community Cancer Consortium   (United States)

^g Columbus CCOP ^*  (United States)

^h MeritCare Hospital   (United States)

Author keywords

antiemetic therapy; delayed nausea; delayed vomiting; gabapentin; randomized controlled trial

Indexed keywords

EID: 84999980723     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28892     Document Type: Article

References (32)

1. Morrow GR, Hickok JT, Burish TG, et al. Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol. 1996;19:199–203.
2. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15:526–536.
3. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472–4478.
4. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–2494.
5. Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110:678–685.
6. Roila F, Donati D, Tamberi S, et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002;10:88–95.
7. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology, 2004.
8. Loprinzi CL, Christensen B, Grendahl B, et al. Standard Antiemetic Order Guidelines. 2000.
9. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261–2268.
10. Watson J, Gonsalves S, Fossa A, et al. The anti-emetic effects of CP-99, 994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol. 1995;115:84–94.
11. Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer. 2001;9:350–354.
12. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001;19:1759–1767.
13. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol. 1999;17:338–343.
14. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999;340:190–195.
15. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002;94:3032–3041.
16. Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol. 2006;4:403–408.
17. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society for Clinical Oncology clinical practice update. J Clin Oncol. 2011;29:4189–4198.
18. Guttuso T Jr, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet. 2003;361:1703–1705.
19. Maneuf YP, Blake R, Andrews NA, et al. Reduction by gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. Br J Pharmacol. 2004;141:574–579.
20. Cruz FM, de Iracema Gomes Cubero D, Taranto P, et al: Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. Support Care Cancer. 2012;20:601–606.
21. Sarkar S, Saha S, Patra N, et al. Role of gabapentin in chemotherapy induced delayed emesis-an Indian experience. Support Care Cancer. 2007;15:688.
22. Pacheco A, Verschraegen C, Mangalik A, et al. A randomized open-label comparison of aprepitant (A) versus gabapentin (G) in the prevention of the refractory nausea and vomiting associated with moderately and severely emetogenic chemotherapy. J Clin Oncol. 2008;26(Suppl):20509.
23. Gralla RJ, Clark RA, Kris MG, et al. Methodology in anti-emetic trials. Eur J Cancer. 1991;27(Suppl 1):S5–S8; discussion S22.
24. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol. 1991;2:107–114.
25. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103–115.
26. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989;7:108–114.
27. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.
28. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005;41:1278–1285.
29. Aapro M, Fabi A, Nole F, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21:1083–1088.
30. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–119.
31. Martin AR, Pearson JD, Cai B, et al. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003;11:522–527.
32. Haiderali A, Menditto L, Good M, et al: Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer. 2011;19:843–851.